AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2020
Feb 5, 2020
29864_dirs_2020-02-05_d4fd8d59-3f4e-4fa2-a8c6-b070d631e1ba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2020-02-03
Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-03 | Common Stock | M | 2156 | $91.05 | Acquired | 38346 | Direct |
| 2020-02-03 | Common Stock | M | 1941 | $86.52 | Acquired | 40287 | Direct |
| 2020-02-03 | Common Stock | S | 500 | $228.89 | Disposed | 39787 | Direct |
| 2020-02-03 | Common Stock | S | 714 | $230.07 | Disposed | 39073 | Direct |
| 2020-02-03 | Common Stock | S | 1306 | $231.25 | Disposed | 37767 | Direct |
| 2020-02-03 | Common Stock | S | 1177 | $231.92 | Disposed | 36590 | Direct |
| 2020-02-03 | Common Stock | S | 400 | $232.87 | Disposed | 36190 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-03 | Stock Option (Right to Buy) | $91.05 | M | 2156 | Disposed | 2026-02-01 | Common Stock (2156) | Direct |
| 2020-02-03 | Stock Option (Right to Buy) | $86.52 | M | 1941 | Disposed | 2027-02-02 | Common Stock (1941) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 882 | Indirect |
| Common Stock | 16190 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $228.89 (range $228.37 to $229.12).
F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $230.07 (range $229.48 to $230.47).
F5: Open market sales reported on this line occurred at a weighted average price of $231.25 (range $230.53 to $231.50).
F6: Open market sales reported on this line occurred at a weighted average price of $231.92 (range $231.54 to $232.50).
F7: Open market sales reported on this line occurred at a weighted average price of $232.87 (range $232.67 to $233.31).
F8: Fully vested.
F9: The option vests in 16 quarterly installments from 02/03/2017.